Adamas Pharmaceuticals, Inc. Provides Preliminary Consolidated Sales Guidance for GOCOVRI for the Fourth Quarter and Full Year Ended December 31, 2018; Expects the Completion of Enrollment for the Phase 3 Inroads Study of ADS-5102
Preliminary full-year unaudited net sales of GOCOVRI are expected to be approximately $34 million, with approximately 15,500 paid prescriptions filled.
The company expects the completion of enrollment for the Phase 3 INROADS study of ADS-5102 extended release capsules for multiple sclerosis walking impairment in the first half of 2019 and release top-line data in the second half of 2019. Continue to advance ADS-4101 towards registration studies.